Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis

Inclusion Criteria

• •Core Study
• •Diagnosis of relapsing multiple Sclerosis (MS)
• •Patients with at least two documented relapses in the previous 2 years or one documented relapse in the last year
• •Patients with an Expanded Disability Status Scale (EDSS) score of 0-6
• •Extension Study
• •A positive Gd-enhanced MRI scan at screening (in case the first MRI scan obtained at screening was negative, a second scan could have been obtained 1 month later)
• •Neurologically stable with no evidence of relapse within 30 days prior to randomization,or during the Screening and Baseline periods.
• •Female patients either post-menopausal, surgically incapable of bearing children, or practicing an acceptable method of birth control. Females of childbearing potential with a negative pregnancy test at baseline prior to entry into the treatment period.